Kayan Dunnigan
A5034070111- SARS-CoV-2 and COVID-19 Research
- Vaccine Coverage and Hesitancy
- COVID-19 Clinical Research Studies
- Influenza Virus Research Studies
- Viral gastroenteritis research and epidemiology
- COVID-19 epidemiological studies
- Animal Virus Infections Studies
- SARS-CoV-2 detection and testing
- Respiratory viral infections research
- Viral Infections and Outbreaks Research
- Long-Term Effects of COVID-19
- COVID-19 and Mental Health
- Retinal and Optic Conditions
- COVID-19 Pandemic Impacts
- Per- and polyfluoroalkyl substances research
- T-cell and B-cell Immunology
- Immunodeficiency and Autoimmune Disorders
- COVID-19 and healthcare impacts
- Hematopoietic Stem Cell Transplantation
- Animal Disease Management and Epidemiology
- Air Quality and Health Impacts
- Quantum Electrodynamics and Casimir Effect
Baylor Scott & White Health
2021-2024
Baylor Scott & White Medical Center - Temple
2021-2024
University of Arizona
2022
Rocky Mountain University of Health Professions
2022
University of Utah
2022
University of Miami
2022
Temple College
2022
Kaiser Permanente Washington Health Research Institute
2020
Center for Surveillance, Epidemiology, and Laboratory Services
2020
Marshfield Clinic
2020
Messenger RNA (mRNA) BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) COVID-19 vaccines have been shown to be effective in preventing symptomatic randomized placebo-controlled Phase III trials (1,2); however, the benefits of these for asymptomatic SARS-CoV-2 (the virus that causes COVID-19) infection, particularly when administered real-world conditions, is less well understood. Using prospective cohorts health care personnel, first responders, other essential frontline workers* eight U.S....
Information is limited regarding the effectiveness of two-dose messenger RNA (mRNA) vaccines BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) in preventing infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) attenuating disease 2019 (Covid-19) when administered real-world conditions.
The BNT162b2 (Pfizer-BioNTech) mRNA COVID-19 vaccine was recommended by CDC's Advisory Committee on Immunization Practices for persons aged 12-15 years (referred to as adolescents in this report) May 12, 2021, and children 5-11 November 2, 2021 (1-4). Real-world data effectiveness (VE) these age groups are needed, especially because when the B.1.1.529 (Omicron) variant became predominant United States December early investigations of VE demonstrated a decline protection against symptomatic...
During the 2019-20 influenza season, influenza-like illness (ILI)* activity first exceeded national baseline during week ending November 9, 2019, signaling earliest start to season since 2009 A(H1N1) pandemic. Activity remains elevated as of mid-February 2020. In United States, annual vaccination against seasonal is recommended for all persons aged ≥6 months (1). each CDC estimates vaccine effectiveness in preventing laboratory-confirmed associated with medically attended acute respiratory...
Workers critical to emergency response and continuity of essential services during the COVID-19 pandemic are at a disproportionally high risk SARS-CoV-2 infection. Prospective cohort studies needed for enhancing understanding incidence symptomatic asymptomatic infections, identifying factors, assessing clinical outcomes, determining effectiveness vaccination.The Research on Epidemiology in Essential Response Personnel (RECOVER) prospective study was designed estimate examine factors...
Per- and polyfluoroalkyl substances (PFAS) are ubiquitous throughout the United States. Previous studies have shown PFAS exposure to be associated with a reduced immune response. However, relationship between serum antibody levels following SARS-CoV-2 infection or COVID-19 vaccination has not been examined. We examined differences in peak response longitudinal decline of antibodies by cohort essential workers measured using an in-house semi-quantitative enzyme-linked immunosorbent assay...
In a multi-center prospective cohort of essential workers, we assessed knowledge, attitudes, and practices (KAP) by vaccine intention, prior SARS-CoV-2 positivity, occupation, their impact on uptake over time.Initiated in July 2020, the HEROES-RECOVER provided socio-demographics COVID-19 vaccination data. Using two follow-up surveys approximately three months apart, KAP, receipt was collected; first survey categorized participants as reluctant, reachable, or endorser.A total 4,803 were...
Abstract Studies have reported that prior-season influenza vaccination is associated with higher risk of clinical infection among vaccinees. This effect might arise from incomplete consideration within-season waning and recent infection. Using data the US Flu Vaccine Effectiveness Network (2011–2012 to 2018–2019 seasons), we found repeat vaccinees were vaccinated earlier in a season by 1 week. After accounting for VE, determined still more likely test positive A(H3N2) (odds ratio, 1.11; 95%...
ABSTRACT BACKGROUND Information is limited on messenger RNA (mRNA) BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) COVID-19 vaccine effectiveness (VE) in preventing SARS-CoV-2 infection or attenuating disease when administered real-world conditions. METHODS Prospective cohorts of 3,975 healthcare personnel, first responders, other essential frontline workers completed weekly testing during December 14 2020—April 10 2021. Self-collected mid-turbinate nasal swabs were tested by qualitative...
Data on the development of neutralizing antibodies (nAbs) against SARS-CoV-2 after infection and vaccination with mRNA COVID-19 vaccines are limited.From a prospective cohort 3975 adult essential frontline workers tested weekly from August 2020 to March 2021 for by reverse transcription-polymerase chain reaction assay irrespective symptoms, 497 participants had sera drawn (170), (327), both (50 population). Serum was collected each vaccine dose. Serum-neutralizing antibody titers...
Abstract Background We sought to evaluate the impact of changes in estimates COVID‐19 vaccine effectiveness on incidence laboratory‐confirmed infection among frontline workers at high risk for SARS‐CoV‐2. Methods analyzed data from a prospective worker cohort estimate by month as well association vaccination, occupation, demographics, physical distancing, and mask use with risk. Participants completed baseline quarterly surveys, each week self‐collected mid‐turbinate nasal swabs reported...
Abstract Background Antibody responses to non–egg-based standard-dose cell-culture influenza vaccine (containing 15 µg hemagglutinin [HA]/component) and recombinant 45 HA/component) during consecutive seasons have not been studied in the United States. Methods In a randomized trial of immunogenicity quadrivalent vaccines among healthcare personnel (HCP) aged 18–64 years over 2 seasons, HCP who received recombinant-HA (RIV) or cell culture–based inactivated (ccIIV) first season (year 1) were...
Abstract Evaluations of vaccine effectiveness (VE) are important to monitor as COVID-19 vaccines introduced in the general population. Research staff enrolled symptomatic participants seeking outpatient medical care for COVID-19-like illness or SARS-CoV-2 testing from a multisite network. VE was evaluated using test-negative design. Among 236 nucleic acid amplification test-positive and 576 aged ≥16 years, mRNA against 91% (95% CI: 83-95) full vaccination 75% 55-87) partial vaccination....
Abstract The extent to which semi-quantitative antibody levels confer protection against SARS-CoV-2 infection in populations with heterogenous immune histories is unclear. Two nested case-control studies were designed within the multisite HEROES/RECOVER prospective cohort of frontline workers study relationship between and first-time post-vaccination reinfection from December 2021 January 2023. All participants submitted weekly nasal swabs for rRT-PCR testing blood samples quarterly...
The extent to which semi-quantitative antibody levels confer protection against SARS-CoV-2 infection in populations with heterogenous immune histories is unclear. Two nested case-control studies were designed within the multisite HEROES/RECOVER prospective cohort of frontline workers study relationship between and first-time post-vaccination reinfection from December 2021 January 2023. All participants submitted weekly nasal swabs for rRT-PCR testing blood samples quarterly following or...
Abstract Evaluations of vaccine effectiveness (VE) are important to monitor as coronavirus disease 2019 (COVID-19) vaccines introduced in the general population. Research staff enrolled symptomatic participants seeking outpatient medical care for COVID-19–like illness or severe acute respiratory syndrome 2 (SARS-CoV-2) testing from a multisite network. VE was evaluated using test-negative design. Among 236 SARS-CoV-2 nucleic acid amplification test-positive and 576 aged ≥16 years, messenger...
Abstract Background Symptoms of COVID-19 including fatigue and dyspnea, may persist for weeks to months after SARS-CoV-2 infection. This study compared self-reported disability among SARS-CoV-2-positive negative persons with mild moderate COVID-19-like illness who presented outpatient care before widespread vaccination. Methods Unvaccinated adults enrolled within 10 days onset at three US Flu Vaccine Effectiveness Network sites were tested by molecular assay. Enrollees completed an...
ABSTRACT Background Data on the development of neutralizing antibodies against SARS-CoV-2 after infection and vaccination with messenger RNA (mRNA) COVID-19 vaccines are limited. Methods From a prospective cohort 3,975 adult essential frontline workers tested weekly from August, 2020 to March, 2021 for by Reverse Transcription- Polymerase Chain Reaction (RT-PCR) assay irrespective symptoms, 497 participants had sera drawn (170), (327), both (50 population). Serum was collected each vaccine...
Background. We sought to evaluate the impact of changes in estimates COVID-19 vaccine effectiveness on incidence laboratory-confirmed infection among frontline workers at high risk for SARS-CoV-2. Methods. analyzed data from a prospective worker cohort estimate by month as well association vaccination, occupation, demographics, physical distancing and mask use with risk. Participants completed baseline quarterly surveys, each week self-collected mid-turbinate nasal swabs reported symptoms....
Abstract Background Symptoms of COVID-19 including fatigue and dyspnea, may persist for weeks to months after SARS-CoV-2 infection. This study compared self-reported disability among SARS-CoV-2-positive negative persons with mild moderate COVID-19-like illness who presented outpatient care before widespread vaccination. Methods Unvaccinated adults enrolled within 10 days onset at three US Flu Vaccine Effectiveness Network sites were tested by molecular assay. Enrollees completed an...
ABSTRACT Introduction In a multi-center prospective cohort of essential workers, we assessed knowledge, attitudes, and practices (KAP) by vaccine intention, prior SARS-CoV-2 positivity, occupation, their impact on uptake over time. Methods Initiated in July 2020, HEROES-RECOVER provided socio-demographics COVID-19 vaccination data. Using follow-up two surveys approximately three months apart, KAP, receipt was collected; the first survey categorized participants as reluctant, reachable, or...